Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
BioLife Solutions, Inc. is a U.S.-based life sciences company that develops and supplies biopreservation tools and services designed to maintain the viability and functionality of biological materials used in cell and gene therapy, biobanking, and broader regenerative medicine applications. The company operates within the biotechnology and life sciences tools industries, focusing on products that support the storage, transport, and processing of biologic materials across the development and commercialization lifecycle.
The company’s primary revenue drivers are proprietary biopreservation media, controlled-temperature cold chain solutions, and integrated services supporting advanced therapies. BioLife Solutions serves biopharmaceutical companies, cell and gene therapy developers, clinical research organizations, and biobanks, with a strategic position as a specialized provider in a niche yet rapidly growing segment of the life sciences supply chain. Founded in 1998, the company initially focused on organ preservation technologies and later expanded into cell and gene therapy–focused biopreservation as those markets matured.
Business Operations
BioLife Solutions generates revenue through several core operating segments centered on biopreservation and cold chain management. Its principal business units include Biopreservation Media, Cell Processing Tools, and Cold Chain Services, which collectively support the handling of biologic materials from research through commercial distribution. Flagship products such as CryoStor and HypoThermosol are widely used for hypothermic and cryogenic preservation of cells and tissues.
The company operates primarily in the United States with international sales and distribution supporting global clinical and commercial programs. BioLife Solutions controls proprietary formulations, manufacturing capabilities, and logistics technologies that are integrated into customer workflows. The company has historically expanded through acquisitions and partnerships to broaden its technology base, although some prior subsidiaries and assets have been divested as part of strategic realignment; details on certain divestitures remain data inconclusive based on available public sources.
Strategic Position & Investments
BioLife Solutions’ strategic direction emphasizes becoming an end-to-end enabling platform for advanced therapies, with a focus on scalability, regulatory compliance, and supply chain reliability. Growth initiatives have included investment in integrated cold chain services, automation-compatible processing tools, and technologies supporting late-stage and commercial cell and gene therapy programs.
The company has completed multiple acquisitions over time to expand its capabilities in cold storage, logistics, and cell processing. Some acquired businesses have since been restructured or divested to sharpen focus on core biopreservation competencies. BioLife Solutions continues to invest in emerging modalities within regenerative medicine, including autologous and allogeneic cell therapies, although specific financial commitments to individual technologies are not always fully disclosed in public filings.
Geographic Footprint
BioLife Solutions is headquartered in the United States and maintains a primary operational presence in North America, which represents its largest revenue base. The company also supports customers across Europe and the Asia-Pacific region through international distribution networks, direct sales activities, and strategic logistics partners.
Its geographic footprint reflects the global nature of cell and gene therapy development, with products and services integrated into clinical trials and commercial programs spanning multiple continents. While manufacturing and core operations are largely U.S.-based, the company’s influence extends internationally through its role in global biologics supply chains.
Leadership & Governance
BioLife Solutions is led by an executive team with experience in life sciences tools, biopharmaceutical manufacturing, and advanced therapies. The leadership emphasizes disciplined capital allocation, customer integration, and long-term value creation aligned with the growth of cell and gene therapy markets.
Key executives include:
- Michael D. Rice – President and Chief Executive Officer
- Troy A. Poole – Chief Financial Officer
- Jeffrey F. Glass – Chief Operating Officer
- Ryan S. McDonald – Chief Commercial Officer
The company operates under a board-governed structure typical of publicly traded life sciences firms, with strategic oversight informed by regulatory, scientific, and commercial considerations.